3-cyano-1-(3-pyridinyl)-2-phenylisourea | 155342-87-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-cyano-1-(3-pyridinyl)-2-phenylisourea
• 英文别名: N-cyano-O-phenyl-N'-(3-pyridyl)isourea；phenyl-(3-pyridyl)-N-cyanocarbinimidate；N-(3-pyridyl)-N'-cyano-O-phenylisourea；Phenyl N'-cyano-N-(3-pyridinyl)imidocarbamate；phenyl N-cyano-N'-pyridin-3-ylcarbamimidate
• CAS: 155342-87-3
• 化学式: C₁₃H₁₀N₄O
• 分子量: 238.249
• InChiKey: QGVOAGRCOQNBBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-cyano-1-(3-pyridinyl)-2-phenylisourea 在 肼 作用下， 以 四氢呋喃 为溶剂， 生成 N³-(pyridin-3-yl)-1H-1,2,4-triazole-3,5-diamine
  参考文献：
  名称：

  Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3

  摘要：

  Tyrosine kinase 2 (TYK2) is required for signaling of interleukin-23 (IL-23), which plays a key role in rheumatoid arthritis. Presented is the design and synthesis of 1,2,4-triazoles, and the evaluation of their inhibitory activity against the Janus associated kinases TYK2 and JAKs 1-3. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.026
• 作为产物：
  描述：

  2-氨基吡啶 、 N-氰基羰亚胺二苯基酯 以 异丙醇 为溶剂， 反应 24.0h， 以74%的产率得到3-cyano-1-(3-pyridinyl)-2-phenylisourea
  参考文献：
  名称：

  Nicorandil analogues containing NO-donor furoxans and related furazans

  摘要：

  The synthesis and in vitro vasodilating properties of hybrid compounds in which furoxan (1,2,5-oxadiazole 2-oxide) moieties, endowed with different NO-donor properties, were substituted for the nitroxy function of Nicorandil are reported. The corresponding cyanoguanidine analogues are also considered. This approach has led to a series of vasorelaxing compounds devoid of affinity for K-ATP channels, whose activity is prevalently due to their ability to activate sGC, at the concentrations of the experiments. Related furazan (1,2,5-oxadiazole) derivatives, unable to release nitric oxide were also prepared and studied for control. The amide analogues of Nicorandil display feeble vasorelaxing action not involving the activation of K+ channels, while in the guanidine analogues, this mechanism seems to underlie this action. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00098-5

文献信息

• PYRIDYL CYANOGUANIDINE DERIVATIVES
  申请人：Zhang Hesheng

  公开号：US20120309797A1

  公开（公告）日：2012-12-06

  Compounds of formula (I) or pharmaceutically acceptable salts thereof, and use for treating cancer thereof are disclosed, wherein, the definitions of X, Y, R 1 , R 2 and n are described in description.

  公式（I）的化合物或其药用盐的使用，以及用于治疗癌症的方法已被披露，其中，X、Y、R1、R2和n的定义在描述中描述。
• Cyanoguanidines as K-channel blockers
  申请人：The Upjohn Company

  公开号：US05567722A1

  公开（公告）日：1996-10-22

  Cyanoguanidine compounds of Formula I and its pharmaceutically acceptable acid addition salts ##STR1## wherein R.sub.1 is hydrogen or methyl; R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.5 cycloalkyl, C.sub.3 -C.sub.5 cycloalkenyl hydroxy methyl, methoxy-C.sub.1 -C.sub.5 alkyl, or R.sub.1 and R.sub.2 are combined to form a C.sub.3 -C.sub.6 carbocyclic ring; R.sub.3 and R.sub.4 are each independently selected to be hydrogen, C.sub.1 -C.sub.4 alkyl, F, Cl, Br, I or CF.sub.3 ; R.sub.5 is hydrogen, F or Cl; R.sub.6 is hydrogen, --NH.sub.2, --NHCH.sub.3, --NHC.sub.2 H.sub.5, --NHCH(CH.sub.3).sub.2, --N(CH.sub.3).sub.2, --N(C.sub.2 H.sub.5).sub.2, NH(CH.sub.2).sub.m -- OC.sub.1 -C.sub.3 alkyl (where m is 2 or 3), --NHC(O)C.sub.1 -C.sub.3 alkyl, Cl or Br; and n is 0 or 1. The compounds of Formula I are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.

  公式I的氰胍胺化合物及其药学上可接受的酸盐添加物，其中R.sub.1为氢或甲基；R.sub.2为C.sub.1 -C.sub.6烷基，C.sub.2 -C.sub.6烯基，C.sub.2 -C.sub.6炔基，C.sub.3 -C.sub.5环烷基，C.sub.3 -C.sub.5环烯基，羟甲基，甲氧基-C.sub.1 -C.sub.5烷基，或R.sub.1和R.sub.2结合形成C.sub.3 -C.sub.6碳环；R.sub.3和R.sub.4各自独立选择为氢，C.sub.1 -C.sub.4烷基，F，Cl，Br，I或CF.sub.3；R.sub.5为氢，F或Cl；R.sub.6为氢，-NH.sub.2，-NHCH.sub.3，-NHC.sub.2 H.sub.5，-NHCH(CH.sub.3).sub.2，-N(CH.sub.3).sub.2，-N(C.sub.2 H.sub.5).sub.2，NH(CH.sub.2).sub.m -OC.sub.1 -C.sub.3烷基（其中m为2或3），-NHC(O)C.sub.1 -C.sub.3烷基，Cl或Br；n为0或1。公式I的化合物是钾通道阻滞剂，用于治疗心血管疾病，如充血性心力衰竭和高血压，以及作为利尿剂。
• Piperazines as P2X7 antagonists
  申请人：Betschmann Patrick

  公开号：US20080076924A1

  公开（公告）日：2008-03-27

  Novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, enantiomers thereof or prodrugs thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  化合物I式的新型化合物或其药学上可接受的盐、代谢物、异构体、对映体或前药，其中取代基如本文所定义，这些化合物可用作治疗剂。
• DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：Pierce C. Albert

  公开号：US20080014189A1

  公开（公告）日：2008-01-17

  The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及蛋白激酶抑制剂。该发明还提供了包含本发明化合物的药物组合物以及使用该组合物治疗各种疾病的方法。
• Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer
  作者：Simone Fratta、Paulina Biniecka、Antonio J. Moreno-Vargas、Ana T. Carmona、Aimable Nahimana、Michel A. Duchosal、Francesco Piacente、Santina Bruzzone、Irene Caffa、Alessio Nencioni、Inmaculada Robina

  DOI：10.1016/j.ejmech.2023.115170

  日期：2023.3

  Cancer cells are highly dependent on Nicotinamide phosphoribosyltransferase (NAMPT) activity for proliferation, therefore NAMPT represents an interesting target for the development of anti-cancer drugs. Several compounds, such as FK866 and CHS828, were identified as potent NAMPT inhibitors with strong anti-cancer activity, although none of them reached the late stages of clinical trials. We present

  癌细胞高度依赖烟酰胺磷酸核糖基转移酶 (NAMPT) 活性进行增殖，因此 NAMPT 代表了抗癌药物开发的一个有趣靶点。FK866 和 CHS828 等几种化合物被确定为具有强抗癌活性的强效 NAMPT 抑制剂，尽管它们都没有达到临床试验的后期阶段。我们在此展示了三个新抑制剂库的制备，这些抑制剂包含 (pyridin-3-yl)triazole、(pyridin-3-yl)thiourea 和 (pyridin-3/4-yl)cyanoguanidine 作为帽/连接单元和呋喃基化合物的尾部位置。体外抗增殖活性在一组实体和血液癌细胞系上进行了评估，大多数合成化合物在 MiaPaCa-2（胰腺癌）、ML2（急性髓系白血病）、JRKT（急性淋巴细胞白血病）、NMLW 中显示出纳摩尔或亚纳摩尔的细胞毒活性（Burkitt 淋巴瘤）、RPMI8226（多发性骨髓瘤）和 NB4（急性髓性白血病），IC